Asset Details
Do you wish to reserve the book?
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Do you wish to request the book?
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
2011
Overview
This comparison of ranibizumab and bevacizumab to treat neovascular age-related macular degeneration showed equivalent efficacy in maintaining visual acuity. Bevacizumab was associated with more serious adverse events (mainly hospitalizations).
In 2005, clinical trials established the efficacy of ranibizumab
1
,
2
(Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use of bevacizumab (Avastin, Genentech), since the drug had a target specificity similar to that of ranibizumab and was available at low cost.
3
,
4
Because the intraocular safety of bevacizumab and the duration of its therapeutic effect were unknown, the drug was usually administered only when there were signs of active . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Cardiovascular Diseases - epidemiology
/ Drug Administration Schedule
/ Female
/ Humans
/ Macular Degeneration - drug therapy
/ Macular Degeneration - pathology
/ Male
